Key Highlights

  • Shares plunged 64.01% in pre-market trading to $5.31, down from a prior close of $14.75, and trading was halted
  • DURAVYU missed the primary endpoint of the LUGANO Phase 3 trial in the full study dataset
  • Company said the miss was driven by a small subgroup of patients who lost vision for reasons unrelated to wet AMD
  • An ad hoc analysis excluding that subgroup showed non-inferiority to on-label aflibercept
  • 52-week range stands at $9.65 to $19.11, with a market Capitalization of $1.24 billion

Shares Halted After Primary Endpoint Miss

EyePoint Pharmaceuticals (NASDAQ:EYPT) shares plunged 64.01% in pre-market trading to $5.31, down from a prior close of $14.75, and trading in the stock was halted after the company disclosed that its experimental eye drug, DURAVYU, failed to meet its primary endpoint in the LUGANO trial, the first of two pivotal Phase 3 studies testing the drug against on-label aflibercept in patients with wet age-related macular degeneration, a leading cause of vision loss.

The company said the trial missed its target of improving vision across the full study population because results were skewed by a small group of patients, representing about 4% of the roughly 211-patient study, who experienced significant vision loss for reasons the company says were unrelated to wet AMD. In an ad hoc analysis excluding that subgroup, DURAVYU showed non-inferiority to on-label aflibercept with a nominal p-value of 0.0096.

What EyePoint Pharmaceuticals Does

EyePoint Pharmaceuticals is a Watertown, Massachusetts based biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal and ocular diseases. Its proprietary Durasert E bioerodible sustained-release technology underpins its lead pipeline candidate, DURAVYU, a selective tyrosine kinase and anti-VEGF inhibitor. The company also markets FDA-approved products including YUTIQ for chronic non-infectious posterior uveitis and has historically commercialized DEXYCU for post-operative ocular inflammation and ILUVIEN for diabetic macular edema through partnerships.

Company Points to Secondary Endpoints Despite the Miss

The company characterized the LUGANO results as demonstrating clinically meaningful outcomes that reinforce DURAVYU's potential to improve the treatment paradigm in wet AMD, pointing to key secondary endpoints including a 42% reduction in treatment burden achieving statistical superiority over on-label aflibercept, high supplement-free rates, a favorable safety profile with redosing, and strong anatomic control through Week 56. However, the primary endpoint miss in the complete dataset represents a significant setback, and the company's post hoc exclusion of the affected patient subgroup to demonstrate non-inferiority is the kind of result that requires independent scrutiny rather than being taken at face value.

Where Things Stand

EyePoint's halt and steep pre-market decline reflect a genuine primary endpoint failure in a pivotal trial, a materially different outcome than the topline success framing the company's own release emphasizes. With a second pivotal trial, LUCIA, still expected in the fourth quarter of 2026 and a potential FDA filing targeted for the first half of 2027, investors will likely need much more clarity on how regulators view the ad hoc analysis before the stock's longer-term outlook can be reassessed.